ARTICLE | Clinical News
Zorblisa: Phase III started
March 30, 2015 7:00 AM UTC
Scioderm began the double-blind, placebo-controlled, international Phase III SD-005 trial to evaluate topical Zorblisa applied over the entire body once daily for 3 months in about 130 patients. Patie...